National Health (Weighted average disclosed price – October 2020 reduction day) Amendment Determination 2020
National Health Act 1953
I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Department of Health, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the National Health Act 1953.
Dated: 9 September 2020
THEA CONNOLLY
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
1 Name of Instrument
(1) This instrument is the National Health (Weighted average disclosed price – October 2020 reduction day) Amendment Determination 2020.
(2) This instrument may also be cited as PB 88 of 2020.
2 Commencement
This instrument commences on the day after it is registered.
3 Amendments to PB 54 of 2020
Schedule 1 amends the National Health (Weighted average disclosed price – October 2020 reduction day) Determination 2020 (PB 54 of 2020).
Schedule 1 Amendments
[1] Schedule 1
after:
77 | Entecavir | Tablet 1 mg (as monohydrate) | Oral | ENTECLUDE | 117.91 |
omit:
78 | Epirubicin | Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL | Injection/intravesical | Epirubicin ACT | 25.49 |
79 | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirube | 50.98 |
80 | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirubicin Accord | 50.98 |
81 | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirubicin ACT | 50.98 |
82 | Epirubicin | Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL | Injection/intravesical | Epirube | 12.75 |
83 | Epirubicin | Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL | Injection/intravesical | Epirubicin ACT | 12.75 |
84 | Etoposide | Powder for I.V. infusion 1 g (as phosphate) | Injection | Etopophos | 342.38 |
85 | Etoposide | Solution for I.V. infusion 100 mg in 5 mL | Injection | Etoposide Ebewe | 34.24 |
86 | Etoposide | Solution for I.V. infusion 100 mg in 5 mL | Injection | Pfizer Australia Pty Ltd | 34.24 |
[2] Schedule 1
after:
228 | Zoledronic acid | Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL | Injection | DBL Zoledronic Acid | 72.79 |
omit:
229 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Aclasta | 97.45 |
230 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Osteovan | 97.45 |
231 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Ostira | 97.45 |
232 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Zoledasta | 97.45 |
substitute:
229 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Aclasta | 97.47 |
230 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Osteovan | 97.47 |
231 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Ostira | 97.47 |
232 | Zoledronic acid | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Zoledasta | 97.47 |
Schedule 2 Amendments
[3] Schedule 2
after:
1,024 | Enoxaparin | Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Enoxaparin Winthrop | 54.37 |
insert:
1,024A | Epirubicin | Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL | Injection/intravesical | Epirubicin ACT | 25.49 |
1,024B | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirube | 50.98 |
1,024C | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirubicin Accord | 50.98 |
1,024D | Epirubicin | Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL | Injection/intravesical | Epirubicin ACT | 50.98 |
1,024E | Epirubicin | Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL | Injection/intravesical | Epirube | 12.75 |
1,024F | Epirubicin | Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL | Injection/intravesical | Epirubicin ACT | 12.75 |
after:
1,125 | Etoposide | Capsule 50 mg | Oral | Vepesid | 391.11 |
insert:
1,125A | Etoposide | Powder for I.V. infusion 1 g (as phosphate) | Injection | Etopophos | 342.38 |
1,125B | Etoposide | Solution for I.V. infusion 100 mg in 5 mL | Injection | Etoposide Ebewe | 34.24 |
1,125C | Etoposide | Solution for I.V. infusion 100 mg in 5 mL | Injection | Pfizer Australia Pty Ltd | 34.24 |
[5] Schedule 2
after:
1,594 | Imipramine | Tablet containing imipramine hydrochloride 25 mg | Oral | Tofranil 25 | 7.11 |
insert:
1,594A | Imipramine | Tablet containing imipramine hydrochloride 25 mg USP | Oral | Imipramine (Leading) | 19.00 |
[6] Schedule 2
after:
1,902 | Levodopa with carbidopa | Tablet 250 mg-25 mg (USP) | Oral | Carbidopa and Levodopa Tablets, USP | 44.63 |
insert:
1,902A | Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Lecteva | 110.74 |
1,902B | Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Carlevent | 110.74 |
1,902C | Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Stalevo 100/25/200mg | 110.74 |
1,902D | Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Lecteva | 121.22 |
1,902E | Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Carlevent | 121.22 |
1,902F | Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Stalevo 150/37.5/200mg | 121.22 |
1,902G | Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Carlevent | 100.26 |
1,902H | Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Lecteva | 100.26 |
1,902I | Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Stalevo 50/12.5/200mg | 100.26 |
1,902J | Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Lecteva | 114.94 |
1,902K | Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Stalevo 125/31.25/200mg | 114.94 |
1,902L | Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Carlevent | 114.94 |
1,902M | Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Carlevent | 130.86 |
1,902N | Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Stalevo 200/50/200mg | 130.86 |
1,902O | Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Lecteva | 130.86 |
1,902P | Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Lecteva | 104.87 |
1,902Q | Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Carlevent | 104.87 |
1,902R | Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Stalevo 75/18.75/200mg | 104.87 |
[7] Schedule 2
after:
1,954 | Losartan | Tablet containing losartan potassium 50 mg | Oral | Cozavan | 7.25 |
insert:
1,954A | Lurasidone | Tablet containing lurasidone hydrochloride 40 mg | Oral | Lurasidone Lupin | 46.48 |
1,954B | Lurasidone | Tablet containing lurasidone hydrochloride 40 mg | Oral | Ardix Lurasidone | 46.48 |
1,954C | Lurasidone | Tablet containing lurasidone hydrochloride 40 mg | Oral | Latuda | 46.48 |
1,954D | Lurasidone | Tablet containing lurasidone hydrochloride 80 mg | Oral | Latuda | 92.96 |
1,954E | Lurasidone | Tablet containing lurasidone hydrochloride 80 mg | Oral | Ardix Lurasidone | 92.96 |
1,954F | Lurasidone | Tablet containing lurasidone hydrochloride 80 mg | Oral | Lurasidone Lupin | 92.96 |
[8] Schedule 2
after:
2,035 | Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | Metformin XR 500 APOTEX | 3.72 |
insert:
2.035A | Metformin | Tablet (prolonged release) containing metformin hydrochloride 500 mg | Oral | Metformin (Medsurge) | 4.01 |
[9] Schedule 2
after:
2,096 | Methylphenidate | Capsule containing methylphenidate hydrochloride 40 mg (modified release) | Oral | Ritalin LA | 38.07 |
insert:
2,096A | Methylphenidate | Capsule containing methylphenidate hydrochloride 60 mg (modified release) | Oral | Ritalin LA | 51.01 |
[10] Schedule 2
after:
2,367 | Nitrazepam | Tablet 5 mg | Oral | Mogadon | 1.48 |
insert:
2,367A | Nitrofurantoin | Capsule 100 mg | Oral | APO-Nitrofurantoin | 14.67 |
2,367B | Nitrofurantoin | Capsule 100 mg | Oral | Macrodantin | 14.67 |
2,367C | Nitrofurantoin | Capsule 50 mg | Oral | Macrodantin | 10.46 |
2,367D | Nitrofurantoin | Capsule 50 mg | Oral | APO-Nitrofurantoin | 10.46 |
[11] Schedule 2
after:
3,224 | Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation) | Inhalation by mouth | Ventolin CFC-free | 3.88 |
insert:
3,224A | Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Zempreon CFC-Free with dose counter | 4.49 |
3,224B | Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by Mouth | Ventolin CFC-Free with dose counter | 4.49 |